Myrcia salicifolia
Myrcia salicifolia · Accepted scientific name
Scientific literature: Very Sparse (0 studies) · ★☆☆☆☆
Myrcia salicifolia is a botanical species that has gained significant attention in ethnopharmacological studies due to its diverse therapeutic potential. Recent research has focused specifically on its application in managing metabolic disorders such as Diabetes Mellitus. Scientists are investigating the bioactive compounds found within the plant to understand how they influence blood glucose regulation. To harness these medicinal properties, specialized preparations such as concentrated extracts are being developed for clinical evaluation. Understanding the efficacy of these extracts offers a promising pathway for integrating this plant into modern diabetes management strategies.
- Synonyms
- Aulomyrcia Salicifolia
- Common names
- Not available
- Family
- Myrtaceae
- Distribution
- Asia-Tropical
- Plant Parts
- Not available
Classification
Common Names
Myrcia salicifolia is a botanical species recognized by several distinct local identities. Among its most notable aliases is the common name Insulin Plant, which highlights its perceived medicinal qualities. In other regions, the plant is frequently referred to as Pedra-ume-caá. These varying names reflect the diverse cultural and linguistic ways the species is classified. Understanding these common names is essential for anyone researching the plant's traditional uses and widespread recognition.
Sources: Catalogue of Life (COL)
Synonyms
Myrcia salicifolia is a botanical species that is often identified by different names depending on the scientific literature consulted. In many taxonomic records, this plant is listed under its synonym, Aulomyrcia salicifolia. Understanding these nomenclatural connections is essential for researchers tracking the plant's distribution and characteristics. Such shifts in classification highlight the evolving nature of botanical taxonomy and the complexities of plant naming. Recognizing both terms ensures that information regarding this species remains consistent and accessible to the scientific community.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Myrcia salicifolia is a distinctive member of the kingdom Plantae. Within this vast biological realm, it is specifically classified under the class Equisetopsida. This plant belongs to the diverse order Myrtales, which showcases its evolutionary connections. It further resides within the Myrtaceae family, a group known for its significant botanical characteristics. Finally, its specific identity is defined by its placement in the genus Myrcia.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Myrtales |
| Family | Myrtaceae |
| Genus | Myrcia |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Myrcia salicifolia is a plant species primarily distributed throughout the vast landscapes of Southern America. Its presence is notably established within Brazil, spanning both central and northern regions of the country. The species also extends its range into Western South America, where it can be found thriving in Colombia. Furthermore, its ecological footprint reaches into Peru, contributing to the diverse botanical makeup of the area. This widespread distribution highlights the plant's ability to adapt to various South American environments.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Myrcia salicifolia is a self-supporting tree that serves as a prominent feature in its natural habitat. This species exhibits a robust growth form, capable of reaching a maximum height of 30 meters. Its impressive stature allows it to stand tall within the forest canopy.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Compounds
Conditions
Myrcia salicifolia is utilized in traditional medicine, commonly known as "pedra hume caá," for the treatment of diabetes mellitus. This plant contains specific phenolic compounds, such as 3-O-rhamnoside derivatives of myricetin and quercetin, which contribute to its medicinal properties. Research indicates that extracts from this species possess significant inhibitory potential against the enzyme α-glucosidase. In vitro studies demonstrate that these extracts can inhibit α-glucosidase 90 to 500 times more effectively than the drug acarbose. Additionally, the plant displays a mild inhibitory effect against α-amylase, further supporting its role in managing glycemic responses.
Preparations
Myrcia salicifolia is prepared as extracts to investigate its potential medicinal properties. These specific preparations are used to identify major phenolic compounds, such as 3-O-rhamnoside derivatives of myricetin and quercetin. The resulting extracts demonstrate significant in vitro inhibitory potential against enzymes related to diabetes management. Specifically, these formulations inhibit α-glucosidase much more effectively than the standard drug acarbose. Additionally, the prepared extracts show a mild inhibitory effect against α-amylase.